136 related articles for article (PubMed ID: 37792671)
1. Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
Tomonaga Y; de Nijs K; Bucher HC; de Koning H; Ten Haaf K
Int J Cancer; 2024 Feb; 154(4):636-647. PubMed ID: 37792671
[TBL] [Abstract][Full Text] [Related]
2. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
5. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.
Liu Y; Xu H; Lv L; Wang X; Kang R; Guo X; Wang H; Zheng L; Liu H; Guo L; Chen Q; Liu S; Qiao Y; Zhang S
BMC Med; 2024 Feb; 22(1):73. PubMed ID: 38369461
[TBL] [Abstract][Full Text] [Related]
6. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
Tomonaga Y; Ten Haaf K; Frauenfelder T; Kohler M; Kouyos RD; Shilaih M; Lorez M; de Koning HJ; Schwenkglenks M; Puhan MA
Lung Cancer; 2018 Jul; 121():61-69. PubMed ID: 29858029
[TBL] [Abstract][Full Text] [Related]
8. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
[TBL] [Abstract][Full Text] [Related]
12. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Jaine R; Kvizhinadze G; Nair N; Blakely T
Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study.
Zhao Z; Du L; Li Y; Wang L; Wang Y; Yang Y; Dong H
JMIR Public Health Surveill; 2022 Jul; 8(7):e36425. PubMed ID: 35793127
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
[TBL] [Abstract][Full Text] [Related]
17. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.
Toumazis I; Cao P; de Nijs K; Bastani M; Munshi V; Hemmati M; Ten Haaf K; Jeon J; Tammemägi M; Gazelle GS; Feuer EJ; Kong CY; Meza R; de Koning HJ; Plevritis SK; Han SS
Ann Intern Med; 2023 Mar; 176(3):320-332. PubMed ID: 36745885
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of lung cancer screening combined with nurse-led smoking cessation intervention: A population-based microsimulation study.
Yuan J; Sun Y; Xu F; Li M; Fan M; Zhang C; Wang K; Li H; Bu X; Yan X; Wang J; Ma J; Zhang G; Chen M; Ren H
Int J Nurs Stud; 2022 Oct; 134():104319. PubMed ID: 35926265
[TBL] [Abstract][Full Text] [Related]
19. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
